KPV and Skin: Reading a Laboratory Result
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

KPV is a three-amino-acid sequence studied in inflammation research. For skin claims, one crucial question is where the experiment happened: in patients, or in a laboratory model? A 2025 study exposed cultured skin cells to particulate pollution and tested KPV. Researchers reported changes in oxidative stress, inflammatory signaling, and cell survival. They also used a three-dimensional skin model. Human-derived cells are still not the same as treating people with eczema, acne, or psoriasis. FDA notes missing human exposure data for KPV drug products. Delivery, clinical benefit, and safety still need careful testing before laboratory findings can support a skin-treatment claim.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Sung et al. (2025): KPV in pollution-exposed keratinocytes and a 3D skin model
https://pubmed.ncbi.nlm.nih.gov/40073467/
Primary in-vitro study

[2] FDA peptide safety information: KPV
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
US regulator

EVIDENCE LIMITATIONS
A PubMed Humans indexing term can describe human-origin cells and does not establish patient research.
No eczema, psoriasis, acne, wound-healing, or cosmetic efficacy claim is supported by this experiment.
Skin-model results cannot establish absorption or safety of an injected product.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/1390999746089643/